Clinical Trials on AMH

Total 754 results

The First Affiliated Hospital of Soochow University

Not yet recruiting

Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients

Relapsed/Refractory AML

China
University Hospital Inselspital, Berne

Recruiting

Drug-screening in AML at Relapse for Targeted Treatment (DARTT-1)

AML

Switzerland
Shenyang Northern Hospital

Recruiting

Baduanjin Sequential Therapy and Cardiac Function of AMI With Reduced EF After PCI (BST-AMI)

AMI

China
Centre Antoine Lacassagne
Acute Leukemia French Association

Not yet recruiting

A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD Relapse/Refractory (R/R) AML (AGORA-1)

AML
Actinium Pharmaceuticals

Withdrawn

Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients

Acute Myeloid Leukemia | Relapsed Adult AML
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

Leukemia, Acute Myeloid (AML)

Japan, United States, Belgium, Canada, France, Germany, Israel, Italy, Korea, Republic of, Poland, Spain, Taiwan, Turkey, United Kingdom
Philogen S.p.A.
Boehringer Ingelheim

Completed

Trial to Find and Investigate a Safe Dose of F16IL2 and BI 836858 in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation (PHIBI)

Acute Myeloid Leukemia (AML) Relapse

Germany
Tarapeutics Science Inc.

Recruiting

A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Relapsed or Refractory Acute Myeloid Leukemia (AML)

China
Tarapeutics Science Inc.

Recruiting

A Study of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Relapsed or Refractory Acute Myeloid Leukemia (AML)

China
Ruijin Hospital

Completed

Cardiac Fibroblast Activation Detected by 68Ga-FAPI PET/MR

Myocardial Remodeling After AMI

China
Chen Suning

Active, not recruiting

Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML

Chemotherapy Effect | AML, Adult

China
University Hospital Inselspital, Berne

Withdrawn

Epacadostat, Cladribine and Cytarabine (ECC) in AML (ECC)

AML | Relapse

Switzerland
Chinese PLA General Hospital
Navy General Hospital, Beijing

Unknown

Chidamide Plus DCAG for Relapsed/Refractory AML

AML | Relapse

China
French Innovative Leukemia Organisation
Novartis Pharmaceuticals

Completed

Phase I Study in RAD 001 Patients With Relapse AML

AML

France
Groupe Francophone des Myelodysplasies
AbbVie

Recruiting

Venetoclax in Patients With MDS or AML in Relapse After AHSCT

AML | MDS

France
Nordic MDS Group

Completed

Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5

AML | MDS

Denmark, Norway, Sweden
PETHEMA Foundation

Terminated

LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML)

AML

Spain
Amgen

Terminated

A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies

Myelodysplastic Syndrome | Relapsed/Refractory AML | Minimal Residual Disease Positive AML

United States, Canada, Germany, Netherlands
Novartis Pharmaceuticals

Completed

Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)

Age-related Macular Degeneration (AMD)

United States
University of Wisconsin, Madison

Terminated

FLT-PET Imaging for MDS

AML | MDS

United States
The First Affiliated Hospital with Nanjing Medical...

Unknown

Treatment of Age-related Macular Degeneration by Fetal Retinal Pigment Epithelial Cells Transplantation

Macular Degeneration | Age Related Macular Degeneration | AMD

China
Novartis Pharmaceuticals

No longer available

Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy (AMLFLT3)

Acute Myeloid Leukemia (AML) With | FLT3 Mutation, Internal Tandem Duplication (ITD) or Tyrosine Kinase Domain (TKD)

United States
BioNova Pharmaceuticals (Shanghai) LTD.

Recruiting

A Study of BN104 in the Treatment of Acute Leukemia

AML, Adult | ALL, Adult

China
MacroGenics

Terminated

Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML) (VOYAGE)

AML

United States, United Kingdom, Germany, Israel, Spain, France, Italy, Netherlands
West Coast Retina Medical Group, Inc.
Genentech, Inc.

Unknown

Genetics Study of Wet Age-Related Macular Degeneration (AMD) Non-Responders to Vascular Endothelial Growth Factor (VEGF) Therapy

Wet AMD

United States
Yonsei University
CardioVascular Research Foundation, Korea

Completed

Efficacy of Early Intensive ROsuvastatin Therapy in Patients With ST-segment Elevation Myocardial Infarction Undergoing PrimARY Percutaneous Coronary Intervention (the ROSEMARY Trial)

ST-segment Elevation AMI

Korea, Republic of
Array BioPharma

Completed

A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors

AML | Advanced and Selected Solid Tumors | High Risk and Very High Risk MDS

United States, Australia, Italy, Spain, France, Switzerland, United Kingdom
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

To Evaluate the Phase I Clinical Study of XZB-0004 in Patients With AML and MDS

AML | MDS

China
Aptevo Research and Development LLC

Recruiting

Study of APVO436 in Patients With AML or MDS

AML | MDS

United States
National Eye Institute (NEI)

Active, not recruiting

Vitamin A Palmitate Supplementation in People With Age-Related Macular Degeneration (and Without Reticular Pseudodrusen) and Delayed Dark Adaptation

AMD

United States
National Eye Institute (NEI)

Completed

Generation of Induced Pluripotent Stem (iPS) Cell Lines From Skin Fibroblast Cells of Participants With Age-Related Macular Degeneration

AMD

United States
Lee's Pharmaceutical Limited

Unknown

TAB014(Drug Code) in Wet( Neovascular)Age-related Macular Degeneration(AMD) Subjects

AMD

China
Zhongnan Hospital

Recruiting

An Open, Single Center, Randomized Controlled Clinical Study of UCB (Cord Blood) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)

UCB (Cord Blood) Microtransplantation in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)

China
Nanjing Chia-tai Tianqing Pharmaceutical

Recruiting

A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies

Relapsed/Refractory Acute Myeloid Leukemia (AML)

China
Children's Hospital of Soochow University

Recruiting

Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML (GMCAII)

Acute Myeloid Leukemia | AML, Childhood

China
Fondazione G.B. Bietti, IRCCS

Completed

Morpho-functional Changes After Oral Supplementation of Antioxidants and Anti-inflammatory Treatment in Age-Related Macular Degeneration. (MACUPREV)

Dry AMD

Italy
Jazz Pharmaceuticals

Approved for marketing

EAP of CPX-351 (VYXEOS) for Patients 60-75 Years of Age With Secondary AML (401)

Secondary AML

United States
Institut de Recherches Internationales Servier

Recruiting

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

Myelodysplastic Syndromes | Relapsed or Refractory Acute Myeloid Leukemia (AML) | Untreated AML | Other IDH1-mutated Positive Hematologic Malignancies

United States, France
The Second Hospital of Shandong University

Not yet recruiting

NK Cell Therapy Recurrent/Refractory Elderly AML

AML | Elderly | Recurrent | Refractory

China
Moorfields Eye Hospital NHS Foundation Trust
King's College London; Cardiff University; University College, London; Newcastle... and other collaborators

Recruiting

Quality-Assured Follow-up of Quiescent Neovascular Age -Related maculaR dEgeneration by Non-medical Practitioners (FENETRE)

AMD

United Kingdom
Mana Therapeutics

Terminated

Study of Mana 312 (Multi Tumor-Associated Antigen T Cells) in Adults With AML/MDS After HSCT

AML/MDS

United States
Celyad Oncology SA
IQVIA Biotech

Completed

DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2 (DEPLETHINK)

AML | MDS

United States, Belgium
Changhua Christian Hospital

Completed

Real World Outcomes of Intravitreal Anti-vascular Endothelial Growth Factors for Neovascular Age Related Macular Degeneration in Taiwan (OIVAEGFFAMDIT)

AMD

Taiwan
Regeneron Pharmaceuticals

Completed

Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection) (RE-VIEW)

Age - Related Macular Degeneration (AMD)

United States
University Hospital, Akershus

Recruiting

Precision Therapy Versus Standard Therapy in AML and MDS in Elderly (PALM)

MDS | AML, Adult

Norway
Coeptis Therapeutics
Duke University

Recruiting

Safety and Efficacy of Allogeneic NK Cell Infusions in Patients With Relapsed/Refractory AML and High Risk MDS

MDS | AML, Adult Recurrent

United States
Immune System Key Ltd
University of Miami Sylvester Comprehensive Cancer Center

Recruiting

Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML

AML | Advanced MDS

United States
The First Hospital of Jilin University

Active, not recruiting

Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT

Relapsed Adult AML | Relapsed Adult ALL

China
PTC Therapeutics

Terminated

Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias

Leukemia, Myeloid, Acute | AML

United States
Tyrogenex
International Drug Development Institute; SynteractHCR

Terminated

X-82 to Treat Age-related Macular Degeneration

Eye Diseases | Macular Degeneration | Retinal Degeneration | Retinal Diseases | Age-Related Macular Degeneration (AMD) | Exudative Age-related Macular Degeneration | AMD | Macular Degeneration, Age-related, 10

United States

Clinical Trials on AMH

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Romania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations